Research Article
Immunophenotypes and Immune Markers Associated with Acute Promyelocytic Leukemia Prognosis
Table 1
Immunophenotypic analysis of de novo APL patients [n (%)].
| | Antigens | Number (N) | Positive rate | Median of positive rate | | 0–10% | 10–20% | 20–40% | 40–60% | 60–80% | 80–100% |
| | cMPO | 16 | 5 (31.3) | | 3 (18.8) | 4 (25) | 2 (12.5) | 2 (12.5) | 38.62 | | CD33 | 132 | 1 (0.8) | | 5 (3.8) | 13 (9.8) | 17 (12.9) | 96 (72.7) | 94.19 | | CD13 | 131 | 5 (2.9) | | 16 (9.2) | 25 (14.4) | 25 (14.4) | 60 (34.5) | 75.86 | | CD117 | 131 | 97 (74.0) | | 20 (15.3) | 9 (6.9) | 5 (3.8) | 0 (0) | 6.14 | | CD9 | 87 | 3 (3.4) | | 9 (10.3) | 10 (11.5) | 23 (26.4) | 42 (48.3) | 78.34 | | CD64 | 102 | 22 (21.6) | | 15 (14.7) | 21 (20.6) | 26 (25.5) | 18 (17.6) | 54.63 | | CD11b | 99 | 89 (89.9) | | 8 (8.1) | 0 (0) | 1 (1.0) | 1 (1.0) | 1.98 | | HLA-DR | 130 | 125 (96.2) | | 4 (3.1) | 0 | 0 | 1 (0.8) | 1.42 | | CD2 | 101 | 89 (88.1) | | 7 (6.9) | 2 (2.0) | 1 (1.0) | 2 (2.0) | 1.55 | | CD19 | 119 | 116 (97.5) | | 2 (1.7) | 1 (0.8) | 0 | 0 | 0.63 | | CD15 | 52 | 51 (98.1) | | 0 | 1 (1.9) | 0 | 0 | 1.33 | | CD71 | 42 | 18 (42.9) | | 15 (35.7) | 4 (9.5) | 5 (11.9) | 0 (0) | 22.52 | | CD34 | 129 | 112 (86.8) | 2 (1.6) | 4 (3.1) | 3 (2.3) | 1 (0.8) | 7 (5.4) | 0.88 | | CD56 | 113 | 107 (94.7) | 2 (1.7) | 2 (1.7) | 1 (0.9) | 1 (0.9) | 0 | 0.4 |
|
|
